|
|
Post by daduke38 on Oct 12, 2014 8:37:32 GMT -5
I am the question man!  I understood Matt to say that they were going to stay at 3 lines until EMA. Now I am not sure if he meant the submittal or the approval, but I don't understand capping sales at $800M. One of the first things SNY said was Israel was good for $200M. The lines take apprx. 6 months from ordering to operation from my understanding. They also got $150M recently and will get another $75M in Nov. Wouldn't it make sense to start adding ASAP? Maybe I am overly optimistic, but my biggest concern is meeting demand. Do they think "A" will only do $600M to $800M in the first year plus+ in the USA? And even if they are right, wouldn't backup production capacity make sense? We know this is a great product and I think (MY opinion) the demand will go viral very quickly. So why not spend $10M of that money to increase production that you know you will need eventually? What am I missing? Thet spend over a Billion developing the drug, but don't want to spend a few million for back-up production? TIA |
|
|
|
Post by jurystillout on Oct 12, 2014 9:51:59 GMT -5
Very good point, if SNY had committed to a volume of sales greater than $800M, MNKD would be foolish to not prepare to fill the order. I think it would be safe to say that if SNY committed to any volume of sales it would be less than $800M, how much lower ?? Is the commitment volume tiered??? I only hope that MNKD insisted on a committed volume of sales to be identified in the partnership contract, this is business 101 when agreeing to an exclusive sales agreement. Does this reflect on the enthusiasm SNY has for this product and is it a window for what we can expect from SNY's marketing plans? The intentions of SNY is the biggest question / concern for me.
|
|
|
|
Post by ezrasfund on Oct 12, 2014 9:58:26 GMT -5
One of the first things SNY said was Israel was good for $200M. How did I miss this info? When did a Sanofi spokesperson make the comment? |
|
|
|
Post by kc on Oct 12, 2014 15:48:33 GMT -5
I have not seen any published comment others than message board speculation about an order from Israel. I would not surprise me since Mann Institute is developing drugs in Israel with their partnership with Israel's Technion. Mann has been a huge supporter of the Technion which is responsible a lot of medical devices and new medicines. From sanofi Israel. Attachment DeletedAttachment Deleted |
|
|
|
Post by daduke38 on Oct 12, 2014 18:07:15 GMT -5
Very good point, if SNY had committed to a volume of sales greater than $800M, MNKD would be foolish to not prepare to fill the order. I think it would be safe to say that if SNY committed to any volume of sales it would be less than $800M, how much lower ?? Is the commitment volume tiered??? I only hope that MNKD insisted on a committed volume of sales to be identified in the partnership contract, this is business 101 when agreeing to an exclusive sales agreement. Does this reflect on the enthusiasm SNY has for this product and is it a window for what we can expect from SNY's marketing plans? The intentions of SNY is the biggest question / concern for me. It is for me, too! So many people on the YMB are screaming about MNKD management, but it's SNY we should be fearing from. If you really think about it, Mnkd for the most part has been reduced to running 1 production facility in this deal. What elsr are they responsible for? That's why I think this is step 1 for an eventual buyout. As far as the Israel comment, it was made about a week after the agreement by the SNY VP of Israeli marketing. Finally, the fact that as far as the public knows, including us, the best sales we could do based on production is at $800M. Don't think that causes people to jump in a buy yet. |
|
|
|
Post by gwb on Oct 12, 2014 20:27:56 GMT -5
Can you post that in English us computer challenged folks ? Thanks
|
|
|
|
Post by mnholdem on Oct 12, 2014 20:35:40 GMT -5
Again, keep in mind that MannKind will not have just 3 lines throughout the 2015 sales year. I'd be quite happy with $1B first year sales, especially with what I posted and think is Sanofi's new marketing strategy. There's more to it, very exciting stuff I've uncovered, that I'll put together in a new thread.
Sanofi is going to crush Lilly and Novo IMHO.
|
|
|
|
Post by brentie on Oct 12, 2014 21:07:20 GMT -5
Very good point, if SNY had committed to a volume of sales greater than $800M, MNKD would be foolish to not prepare to fill the order. I think it would be safe to say that if SNY committed to any volume of sales it would be less than $800M, how much lower ?? Is the commitment volume tiered??? I only hope that MNKD insisted on a committed volume of sales to be identified in the partnership contract, this is business 101 when agreeing to an exclusive sales agreement. Does this reflect on the enthusiasm SNY has for this product and is it a window for what we can expect from SNY's marketing plans? The intentions of SNY is the biggest question / concern for me. It is for me, too! So many people on the YMB are screaming about MNKD management, but it's SNY we should be fearing from. If you really think about it, Mnkd for the most part has been reduced to running 1 production facility in this deal. What elsr are they responsible for? That's why I think this is step 1 for an eventual buyout. As far as the Israel comment, it was made about a week after the agreement by the SNY VP of Israeli marketing.
Finally, the fact that as far as the public knows, including us, the best sales we could do based on production is at $800M. Don't think that causes people to jump in a buy yet.Is this what you're talking about? I don't see anything about a $200 million order. August 18, 2014 | Pharmaceutical company Sanofi Inhaled insulin AFREZZA may soon appear in Israel Вдыхаемый инсулин AFREZZA может скоро появится в Израиле Pharmaceutical company Sanofi and American biopharmaceutical corporation MannKind, engaged in research of cancer and diabetes, as well as the development of therapeutic drugs against these diseases, have signed an agreement for the distribution of the first of its kind inhaled insulin AFREZZA. A new form of insulin for the treatment of type 1 and type 2 received considerable support from the FDA (FDA Office of the Food and Drug Administration in the United States), because now the use of insulin by diabetic patients of the first and the second type is much easier and painless. AFREZZA is a revolutionary innovation: human insulin analog, equal in potency of human insulin and charged into the cartridge (inhaler) for inhalation. AFREZZA - a rapid-acting insulin, which, like their counterparts (eg, insulin Apidra), simulates the response of the body to increase blood sugar levels after a meal, soaked in parallel with the highest food. This insulin is required to use, in addition to basal insulin (eg Lantus). Application of rapid-acting insulin as a food insulin has the following advantages: * rapid onset of action allows you to inject insulin just before eating, when we already know the amount of food that will be eaten now, * in some cases when it is difficult to determine in advance the amount of food, including young children, the injection can be made after a meal by the dose depending on the amount of food * due to the fact that the effect of insulin corresponds approximately VHF time enhance glucose blood after a meal, you can not snack between meals. However, one disadvantage of using such are part of the daily insulin injections. Birinboym Roni, CEO of Sanofi in Israel: "Inhaled insulin AFREZZA save diabetics from having to do injections and greatly facilitate their life. This is a real revolution in the world of pharmacology. Our company will do everything necessary to deliver as soon as possible this insulin in Israel ". AFREZZA go on sale in America in early 2015.
potrebitel.israelinfo.co.il/health-beauty/sanofi/8871
|
|
|
|
Post by daduke38 on Oct 13, 2014 5:57:07 GMT -5
Can you post that in English us computer challenged folks ? Thanks Sorry, I did rush that post a bit!  |
|
|
|
Post by daduke38 on Oct 13, 2014 6:28:14 GMT -5
Here is the link, I think: karman.zahav.ru/Articles/6714/sanofiObviously its not in English. I tred to find the P.R. but no luck. I do distinctly remember reading the P.R. about a week after the agreement in English, but can't find it. |
|
|
|
Post by kc on Oct 13, 2014 9:58:46 GMT -5
|
|
|
|
Post by brentie on Oct 13, 2014 10:13:00 GMT -5
It's the same one I posted earlier in this thread.(Inhaled insulin AFREZZA may soon appear in Israel) |
|
|
|
Post by daduke38 on Oct 13, 2014 10:38:53 GMT -5
|
|
|
|
Post by brentie on Oct 13, 2014 11:09:24 GMT -5
Yeah, at a September 28,2010 conference (I don't know the name) Al said...
"There is a small country that wants to buy $200 million a year from us. This would cost a million dollars a month to ship. So we will formulate the product here and fill in this country."
|
|
|
|
Post by cybergym66 on Oct 13, 2014 12:44:19 GMT -5
Found these posts....
Jun 23, 2014 15:30:36 GMT -4 ezrasfund said:
The $200M order is taking on the character of an urban legend. In 2010 before the 1st CRL Al Mann said that he had been talking to health officials in a "middle eastern country" who said they would like to place an order for Afrezza, which could be $200M per year. This was an off the cuff remark by Al, made only once and never referred to again. It probably related to a visit to Israel (there is an Al Mann Institute at the Technion) and was just Al reporting on a casual conversation. Why this one remark has taken on a life of its own is a good study in how rumors are born and sometimes never die. It also points out why Al is seldom the presenter in public forums, as he sometimes goes off script and makes casual (but not necessarily untrue) remarks. It did cost them $16M one time, however.
Jun 23, 2014 17:38:55 GMT -4 mannmade said:
After the last shareholder meeting I went up to Hakan and asked him about the 3rd world country out there waiting on approval for Afrezza in the US before placing an order and he told me they were still in the conversation but would likely take at least six months after approval for anything to happen with it if moved forward.
|
|
